期刊文献+

慢性粒细胞白血病额外染色体异常在加速期和急变期的意义 被引量:8

The Meaning of Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia at Accelerated Phase and Blastic Crisis
下载PDF
导出
摘要 目的探讨慢性粒细胞白血病(CML)的染色体变化在慢性期(CP)、加速期(AP)、急变期(BC)的特征,并分析遗传学变化对CML加速期、急变期的治疗和预后判断的意义。方法24—48h短期培养法,R显带,对63例患者的遗传学资料进行回顾性分析。结果63例中Ph染色体阳性61例(96.8%),Ph阴性但BCR/ABL阳性2例(3.2%),而61例Ph染色体阳性的患者中,典型Ph易位51例,非典型Ph染色体为10例(变异易位1例,伴有其他染色体平衡易位的4例,结构畸变2例,伴有超二倍体核型1例,双Ph1例,-Y1例),1例首诊为加速期,4例在1年内加速或急变。在51例典型Ph易位的患者中,5例形态学加速或急变,遗传学无额外染色体改变,6例遗传学出现额外染色体异常的同时或之后表现为加速或急变。结论染色体核型分析是CML诊断、临床分期及判断预后,指导治疗不可缺少的实验室指标,对预测CML加速、急变有重要的意义。 Objective To study cytogenetic features of chromosome in chronic myelogenous leukemia ( CML). To analyze the signif- icance of genetic alterations in diagnosis, treatment and prediction of prognosis at different stages of CML. Methods Chromosome for bone marrow or peripheral blood cells was prepared by 24 -48h short term culture. Analysis of genetic data were performed by R - band ing. Results Of 63 cases, 2 cases were detected Ph negative but BCR/ABL positive,61 cases were Ph chromosome( 93. 85% ). Of the 61 cases, 51 cases were detected typical Ph chromosome,and 10 patients had atypical Ph chromosome,including variant translocation in 1 case,with other chromosome balanced translocation in 4 cases, structural aberration in 2 cases, with hyperdiploid karyotype in 1 case, double Ph in 1 case, - Y in 1 case. The first diagnosis in 1 cases for accelerated phase, and 4 cases in 1 years to accelerated or blast cri- sis. In 51 patients with typical Ph, 5 patients without additional chromosome changes were morphological accelerated or blastic crisis,and 6 patients with additional chromosomal abnormalities of genetics at the same time or after were accelerated or blastic crisis. Conclusion Analysis of chromosome karyotypes was important laboratory index in prediction of prognosis of CML.
出处 《医学研究杂志》 2014年第1期108-110,共3页 Journal of Medical Research
关键词 慢性粒细胞白血病 额外染色体异常 预后 Chronic myeloid leukemia Additional chromosomal abnormalities Prognosis
  • 相关文献

参考文献10

  • 1张之南;沈悌.血液病诊断及疗效标准[M]北京:科学技术出版社,2007. 被引量:1
  • 2Morris CM. Chronic myeloid leukemia:cytogenetic methods and applications for diagnosis and treatment[J].{H}Methods in Molecular Biology,2011.33-58. 被引量:1
  • 3De Melo VA,Milojkovic D,Marin D. Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked philadelphia rearrangements[J].{H}Cancer Genetics and Cytogenetics,2008.111-115. 被引量:1
  • 4Virgili A,Brazma D,Reid AG. FISH mapping of PhiladelPhia negative BCR/ABL1 positive CML[J].Molecular Cytogenetics,2008.1-13. 被引量:1
  • 5Bennour A,Bellaaj H,Ben Youssef Y. Molecular cytogenetic characterization of philadelphia-negative rearrangements in chronic myeloid leukemia patients[J].{H}Journal of Cancer Research and Clinical Oncology,2011.1329-1336. 被引量:1
  • 6Wadhwa J,Szydlo RM,Apperley JF. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia[J].{H}Blood,2002,(7):2304-2309. 被引量:1
  • 7Johanson B,Fioretos T,Mitelman F. Cytogenetic and molecular genetic evolution of chronc myloid leukemia[J].{H}ACTA HAEMATOLOGICA,2002.76-94. 被引量:1
  • 8Reid AG,Huntly B J,Grace C. Survival implications of molecular heterogeneity in variant philadelphia-positive chronic myeloid leukaemia[J].{H}British Journal of Haematology,2003.419-427. 被引量:1
  • 9Muvarak N,Nagaria P,Rassool FV. Genomic Instability in chronic myeloid leukemia:tTargets for therapy[J].Curr Hematol Malig Rep,2012.94-102. 被引量:1
  • 10Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation[J].Curr Hematol Malig Rep,2012.87-93. 被引量:1

同被引文献51

  • 1张莉,魏旭东,房佰俊,周健,符粤文,李玉富,朱兴虎,宋永平.格列卫治疗慢性粒细胞白血病临床观察[J].中国实用医刊,2010,37(15):43-45. 被引量:2
  • 2吴炜,薛永权,吴亚芳,潘金兰,沈娟.Ph染色体阳性慢性粒细胞白血病衍生9号染色体缺失的FISH研究[J].中华血液学杂志,2006,27(3):183-186. 被引量:12
  • 3姜道滋,陈志妹,楼基余,王云贵,梁毅,金洁.1193例慢性粒细胞白血病细胞及分子遗传学分析[J].中华血液学杂志,2007,28(1):1-5. 被引量:19
  • 4l张之南,郝玉书,赵永强.血液病学[M].2版.北京:人民卫生出版社,2012:459-461. 被引量:17
  • 5Gallioli P, Abraham SA, Holyoake TL. Hurdles to- ward a cure for CML:the CML stem cell[J]. Hema- tol Oncol Clin North Ame,2011,25(5) ..951-966. 被引量:1
  • 6Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia[J]. Clin Cancer Res, 2009, 15(24) :7519-7527. 被引量:1
  • 7Reece-Smith AM, MacGoey P, Shah MA, et al. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era[J]. Eur J Surg Oncol,2012,38(6) :484-489. 被引量:1
  • 8Tefferi A,Dewald G W, Litzow M L. et al. Chronic myeloid leu kemia:current application of cytogenetics and molecular testing for diagnosis and treatment [J]. Mayo Clin Proc, 2005.80 (3) : 390. 被引量:1
  • 9Cortes J E,TaIpaz M,Giles F,et al. Prognostic significance of cy togenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy[J]. Blood,2003,101 (10): 3794-3800. 被引量:1
  • 10Johansson B, Fiorelos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia [J]. Aeta Haema- tol,2002,107(2) : 76. 被引量:1

引证文献8

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部